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Findings
Table 3: PONV Proportion in 24 hours* (n=5,365)
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• A retrospective, EBP project was conducted at Providence 
Sacred Heart Medical Center (PSHMC) and Providence Holy 
Family Hospital (PHFH) in Spokane, WA.
• Permission was obtained by the facility and exemption 
determination was granted by the IRB.
• Patient data was securely extracted and stored in a HIPPA 
complaint REDCap database. Patient data was fully de-
identified. Data extraction included all surgeries receiving 
general anesthesia from October 1, 2018, to September 30, 
2019.
• Inclusion criteria: Adult patients 18-90 years old, general surgery 
(ETT, LMA) using volatile inhalational agents, admitted for 24hrs. 
• Exclusion Criteria: Pediatric, obstetric, direct admission to ICU, 
postoperative intubation requirements in PACU. 
• PONV outcome was determined by nursing documentation of 
PONV scale or administration of antiemetic medication.
• Descriptive data analysis was completed and stratified by 
ondansetron timing. Independent risk factors was determined 
and controlled for using a binary logistic regression. Level of 
significance set at 0.05. 
The literature reports approximately 30% of patients who undergo 
general anesthesia will be affected by PONV.1,2,4 In addition, 
research evidence supports ondansetron administration during 
emergence of anesthesia as an avenue to combat the incidence of 
PONV.4 This project mirrored the literature by correlating a 
relationship between ondansetron timing administration on 
emergence and reducing the risk of PONV at 2, 6, and 24 hours.  
When controlling for Apfel risk factors and confounding bias, this 
project’s PONV incidence was consistent with literature, depicting a 
reduction in PONV incidence at 2, 6, and 24 hours. The prevalence 
of a rescue antiemetic medication at 2, 6, and 24 hours 
postoperatively was also statistically significant for the emergence 
group when compared to the induction group. 
Understanding the pharmacokinetics of ondansetron, especially its 
half-life of 3.8 (+/- 1) hours, provides insight regarding the length of 
time serotonin receptors may be blocked, and thus prevention of 
subsequent PONV occurrences.6
Of the patients that received ondansetron at PSHMC and PHFH, 
71% of patients received ondansetron on emergence. Anesthesia 
providers should continue to tailor prophylactic antiemetic 
administration based on patient selection and antiemetic 
pharmacokinetic profiles.
Addressed as a national quality initiative by the Centers for 
Medicare and Medicaid Services (CMS), postoperative nausea and 
vomiting (PONV) is a vexing complication requiring further attention 
by anesthesia providers.3 Medication optimization is an area of 
focus to address this complication.4 Ondansetron, a selective 5-
hydroxytryptophan subtype 3 (5-HT3) receptor antagonist, is 
effective and considered the “gold standard” in the prevention of 
PONV.4 GlaxoSmithKline™ suggests administering Zofran® 
(ondansetron) before the induction of anesthesia.5 These directions 
are in contrast to the synthesis of the research evidence, which 
supports increased effectiveness of ondansetron when administered 
30 minutes before emergence from anesthesia.4
The purpose of this evidence-based practice (EBP) project was to 
evaluate ondansetron timing, report the incidence proportion of 
PONV among adult general surgical patients and evaluate the 
prevalence of rescue antiemetics utilized at 2, 6, and 24 hours 
postoperatively. 
Table 1: Baseline Demographic and Clinical Characteristics
Variable OR 95% CI P Value
Ondansetron timing:
Emergence 0.79 0.69 – 0.89 <0.0001
Table 2: PONV Proportion Based on Ondansetron Timing





Risk RR 95 % CI P-value
0 – 2 hrs
Emergence 1,387 2,678 34% 0.77 0.72 – 0.82 <0.0001
Induction 822 1,021 45%
0 – 6 hrs
Emergence 1,818 2,247 45% 0.81 0.77 – 0.86 <0.0001
Induction 1,013 830 55%
0 – 24 hrs
Emergence 2,249 1,816 55% 0.88 0.84 – 0.92 <0.0001
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Correlation of Ondansetron Timing in Postoperative Nausea and Vomiting: 
A Retrospective Evaluation Amongst Adult Patients Receiving General Anesthesia
(N=8,365) %
Apfel risk factors:
Female gender 4,413 54%
Non-smoker 6,527 79%
Postoperative opioid use 4,755 59%











Age (years) 61 16
Number of Apfel risk factors 2 1
Median IQR
Duration in PACU 69 53-92
Duration of surgery (minutes) 144 110-201
*Fully adjusted model controlling for Apfel risk factors, age < 50 years, case duration, 
high risk procedures (gynecological, cholecystectomy, and laparoscopy)
